Pfizer faces growth challenges with patent losses and waning COVID sales. Selling an ATM Put option expiring Nov'25 could ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

The U.S. does not buy drugs directly for a national health system, as countries such as England and Germany do, instead ...

Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...

PFE stock is likely to be a great pick for value investors, considering its cheap valuation, as well as for income investors ...

Pfizer's (NYSE: PFE) shares have been southbound for the better part of three years, partly because it was unable to repeat its incredible financial performance during the early pandemic years. At ...

Pfizer sold the five-building facility on Science Center Drive in Torrey Pines to BioMed Realty, a San Diego-based firm owned ...

Despite the challenges, including what CSL CEO Paul McKenzie has described as a fragmented U.S. healthcare system, the blood ...

Analysts are intrested in these 5 stocks: ( ($AFRM) ), ( ($GRAB) ), ( ($VKTX) ), ( ($PFE) ) and ( ($LLY) ). Here is a ...

You may know 175-year-old pharmaceutical company Pfizer (NYSE: PFE) best for its COVID-19 vaccine, but investors have long ...

Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

The fourth beaten-down stock with an apparent price dislocation that I bought during Wall Street's historic volatility is ...